Trial results favor prasugrel over ticagrelor after coronary stenting

Prasugrel reduced large cardiovascular events to the aforesaid grade arsenic ticagrelor but with little large bleeding aft coronary stenting successful patients with acute coronary syndromes, according to results from the SWITCH SWEDEHEART proceedings presented successful a Hot Line league astatine ESC Congress 2026 and published simultaneously successful the New England Journal of Medicine.